[Click e-Stock] "Koh Young Sees Increased Server Demand Driven by Expanded AI Investment"

On November 10, iM Securities projected that Koh Young Technology would continue its growth through artificial intelligence (AI) and robotics.

In the third quarter of this year, Koh Young Technology posted consolidated sales of 60.3 billion won and an operating profit of 4.7 billion won. These figures represent increases of 30.2% and 575.7%, respectively, compared to the same period last year.

Lee Sangheon, a researcher at iM Securities, stated, "The Americas region achieved the highest quarterly sales ever, driving the company's overall growth," adding, "Sales in the Americas reached 22.4 billion won in the third quarter of this year, up 61.2% year-on-year."

He further explained, "Sales in the Americas increased thanks to rising demand for servers, driven by expanded investments related to AI," and added, "As Taiwanese companies increase their investments in the Americas as part of the AI ecosystem, new demand for servers is also growing."

He emphasized, "Server-related sales amounted to 16.8 billion won in the third quarter of this year, up 66.3% from the same period last year," and projected, "The increase in server demand, driven by expanded AI-related investments, will continue."

The researcher analyzed, "As hospital demand for neurosurgical medical robots is rapidly increasing, the company's valuation is expected to be reassessed as it begins full-scale sales in the U.S. market next year."

He introduced, "Koh Young Technology's neurosurgical medical robot, Geniant Cranial, received FDA 510(k) clearance in the United States this January." He also noted, "There are a total of 1,437 advanced neurosurgery hospitals in the U.S. where neurosurgical medical robots can be sold. The company plans to focus its market strategy on 301 hospitals selected as priority targets."

He added, "In July, Geniant Cranial was installed at a major U.S. hospital not just for testing, but for actual sales," and expressed his expectation that "as it is utilized in real surgeries, sales will be recognized in the coming months."

원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.